Despite compelling growth prospects, the drug repositioning Market faces notable commercial and regulatory hurdles. One of the primary challenges involves intellectual property (IP) protection. Securing strong patents for a drug that is already off-patent or available as a low-cost generic can be difficult. Without clear patent protection for novel uses, formulations, or dosage regimens, pharmaceutical firms struggle to secure a return on investment for secondary clinical trials.

Another operational challenge is navigating complex regulatory frameworks when repurposing older compounds. Demonstrating efficacy in a new indication often requires conducting phase II and phase III clinical trials, which still demand substantial financial commitment and regulatory compliance. Additionally, generic competition can cannibalize market share if physicians prescribe lower-cost off-label generic versions rather than newly approved repositioned brand-name treatments.

For strategic recommendations, risk assessments, and key vendor profiles, explore the comprehensive drug repositioning Market analysis.

Looking forward, the long-term outlook for drug repositioning remains bright. As artificial intelligence models mature, regulatory frameworks adapt to repurposed drugs, and biopharmaceutical developers continue prioritizing cost-effective discovery strategies, drug repositioning will remain an indispensable pillar of modern medical innovation.